Loading news...
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help accelerate drug discovery through artificial intelligence.
The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.
SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025 ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 7:30 a.m.
SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2025 following the close of market on Thursday, February 5, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.
Cerity Partners LLC boosted its position in Illumina, Inc. (NASDAQ: ILMN) by 23.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 125,387 shares of the life sciences company's stock after acquiring an additional 23,417 shares during the
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Veteran genomics leader joins Illumina to advance global medical strategy Illumina chief commercial officer to depart for role as a life science tools company CEO SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ: ILMN) announced the appointment of Eric D. Green, M.D.
TAIPEI, Taiwan, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Illumina Taiwan Biotechnology Co., Ltd., and Precision Medicine Asia, Limited (PREMIA), a leading Asian cancer clinical-genomic screening network, today announced the formation of a strategic partnership that will expand access to comprehensive genomic profiling (CGP) for all eligible oncology patients across the Chang Gung Memorial Hospital (CGMH) system. This partnership also aims to support the creation of an Asia-wide clinical-genomic oncology database to advance precision oncology.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Integrated software, AI-driven analytics, and frictionless workflows enable customers to harness the full power of biological insights SAN DIEGO, Jan. 6, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the release of Illumina Connected Multiomics, a powerful cloud-based research software platform to analyze and visualize multiomic and multimodal biological data at scale. As multiomic datasets grow rapidly in size and complexity, researchers need easy-to-use tools to integrate information across transcriptomics, genomics, proteomics, epigenetics, and more.
Generali Asset Management SPA SGR increased its holdings in shares of Illumina, Inc. (NASDAQ: ILMN) by 51.6% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 22,249 shares of the life sciences company's stock after purchasing an additional 7,574 shares during the period. Generali Asset Management
Diversified Trust Co acquired a new position in shares of Illumina, Inc. (NASDAQ: ILMN) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 6,590 shares of the life sciences company's stock, valued at approximately $626,000. Other institutional investors and hedge
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina (ILMN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Illumina, Inc. (NASDAQ: ILMN - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors bought 4,552 call options on the company. This represents an increase of approximately 168% compared to the average volume of 1,700 call options. Wall Street Analyst Weigh In Several research firms recently weighed in on ILMN.
U.S. stocks are heading toward the end of the year with clear momentum, as the major indexes continue to hover near record levels. While short-term pauses have appeared, they have been shallow, suggesting that investors are positioning for a constructive finish to the year and a positive handoff into the new one.